JP2010280671A5 - - Google Patents

Download PDF

Info

Publication number
JP2010280671A5
JP2010280671A5 JP2010157093A JP2010157093A JP2010280671A5 JP 2010280671 A5 JP2010280671 A5 JP 2010280671A5 JP 2010157093 A JP2010157093 A JP 2010157093A JP 2010157093 A JP2010157093 A JP 2010157093A JP 2010280671 A5 JP2010280671 A5 JP 2010280671A5
Authority
JP
Japan
Prior art keywords
epo
erythropoietin
diabetes
manufacture
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2010157093A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010280671A (ja
Filing date
Publication date
Priority claimed from DE10234192A external-priority patent/DE10234192B4/de
Application filed filed Critical
Publication of JP2010280671A publication Critical patent/JP2010280671A/ja
Publication of JP2010280671A5 publication Critical patent/JP2010280671A5/ja
Withdrawn legal-status Critical Current

Links

JP2010157093A 2002-07-26 2010-07-09 エリスロポエチンの使用 Withdrawn JP2010280671A (ja)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10234192A DE10234192B4 (de) 2002-07-26 2002-07-26 Verwendung von Erythropoetin

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2004525322A Division JP4727988B2 (ja) 2002-07-26 2003-07-25 エリスロポエチンの使用

Publications (2)

Publication Number Publication Date
JP2010280671A JP2010280671A (ja) 2010-12-16
JP2010280671A5 true JP2010280671A5 (enExample) 2011-02-03

Family

ID=30128436

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2004525322A Expired - Fee Related JP4727988B2 (ja) 2002-07-26 2003-07-25 エリスロポエチンの使用
JP2010157092A Withdrawn JP2010280670A (ja) 2002-07-26 2010-07-09 エリスロポエチンの使用
JP2010157093A Withdrawn JP2010280671A (ja) 2002-07-26 2010-07-09 エリスロポエチンの使用
JP2010157094A Withdrawn JP2010280672A (ja) 2002-07-26 2010-07-09 エリスロポエチンの使用

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP2004525322A Expired - Fee Related JP4727988B2 (ja) 2002-07-26 2003-07-25 エリスロポエチンの使用
JP2010157092A Withdrawn JP2010280670A (ja) 2002-07-26 2010-07-09 エリスロポエチンの使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2010157094A Withdrawn JP2010280672A (ja) 2002-07-26 2010-07-09 エリスロポエチンの使用

Country Status (26)

Country Link
US (4) US7745387B2 (enExample)
EP (3) EP1779862B1 (enExample)
JP (4) JP4727988B2 (enExample)
KR (2) KR20050026513A (enExample)
CN (3) CN101099860B (enExample)
AT (2) ATE360436T1 (enExample)
AU (2) AU2003255290B2 (enExample)
BR (1) BR0312981A (enExample)
CA (2) CA2493598A1 (enExample)
CY (2) CY1108052T1 (enExample)
DE (3) DE10234192B4 (enExample)
DK (2) DK1526867T3 (enExample)
EA (3) EA200801236A1 (enExample)
ES (2) ES2345673T3 (enExample)
HR (3) HRP20100187A2 (enExample)
IL (2) IL166401A0 (enExample)
IS (3) IS2671B (enExample)
MX (1) MXPA05001120A (enExample)
NO (1) NO20051002L (enExample)
PL (2) PL374874A1 (enExample)
PT (2) PT1779862E (enExample)
SG (1) SG177004A1 (enExample)
SI (2) SI1526867T1 (enExample)
UA (2) UA94913C2 (enExample)
WO (1) WO2004012759A2 (enExample)
ZA (1) ZA200500726B (enExample)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7199102B2 (en) 2000-08-24 2007-04-03 The Regents Of The University Of California Orally administered peptides synergize statin activity
US7723303B2 (en) 2000-08-24 2010-05-25 The Regents Of The University Of California Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response
DE10234192B4 (de) 2002-07-26 2009-11-26 Epoplus Gmbh Co.Kg Verwendung von Erythropoetin
PT1660115E (pt) * 2003-07-29 2011-08-24 Dompe Spa ASSOCIAÇÃO FARMACjUTICA DE G-CSF E DE PLGF ÚTIL NA MOBILIZAÇÃO DE CÉLULAS ESTAMINAIS DO SANGUE
ES2346226T3 (es) * 2003-12-30 2010-10-13 Augustinus Bader Uso de la eritropoyetina para la regeneracion de tejido hepatico.
DE102004004509B4 (de) * 2004-01-23 2010-07-01 Epoplus Gmbh Co.Kg Einsatz von niedrig dosiertem Erythropoietin zur Stimulation endothelialer Vorläuferzellen sowie zur Organregeneration und Progressionsverlangsamung von Endorganschäden
KR20070089996A (ko) 2004-12-06 2007-09-04 더 리전트 오브 더 유니버시티 오브 캘리포니아 세동맥의 구조 및 기능의 개선 방법
AR053416A1 (es) 2005-11-10 2007-05-09 Protech Pharma S A Combinacion de glicoisoformas para el tratamiento o prevencion de la septicemia, linea celular transgenica productora de glicoformas de eritropoyetina, composicion farmaceutica que comprende a dicha combinacion, procedimientos para obtener la linea celular, procedimiento para producir dicha combinac
BRPI0618947B1 (pt) 2005-11-23 2022-07-19 Acceleron Pharma Inc Polipeptídeo actriia que se liga à ativina, polinucleotídeo isolado, polinucleotídeo recombinante, métodopara preparar um polipeptídeo actriia que se liga à ativina, preparação farmacêutica e uso de uma proteína de fusão actriia-fc para promover o crescimento ósseo e inibir a ressorção óssea
US8128933B2 (en) 2005-11-23 2012-03-06 Acceleron Pharma, Inc. Method of promoting bone growth by an anti-activin B antibody
CN101460188B (zh) * 2006-06-07 2013-09-04 国立大学法人德岛大学 使用促红细胞生成素的局部缺血疾病的治疗
MX2009003441A (es) * 2006-09-29 2009-10-16 Centocor Ortho Biotech Inc Agonistas del receptor de eritropoyetina humana, composiciones, metodos y usos para prevenir o tratar condiciones relacionadas con la intolerancia a la glucosa.
US8975374B2 (en) * 2006-10-20 2015-03-10 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical composition comprising anti-HB-EGF antibody as active ingredient
JP5378795B2 (ja) * 2006-10-20 2013-12-25 中外製薬株式会社 抗ｈｂ−ｅｇｆ抗体を有効成分として含む医薬組成物
AU2007311946A1 (en) 2006-10-20 2008-04-24 Forerunner Pharma Research Co., Ltd. Anti-cancer agent comprising anti-HB-EGF antibody as active ingredient
US8895016B2 (en) 2006-12-18 2014-11-25 Acceleron Pharma, Inc. Antagonists of activin-actriia and uses for increasing red blood cell levels
WO2008086025A2 (en) * 2007-01-10 2008-07-17 Edison Pharmaceuticals, Inc. Treatment of respiratory chain disorders using compounds having erythropoietin or thrombopoietin activity
TW201627320A (zh) 2007-02-02 2016-08-01 艾瑟勒朗法瑪公司 衍生自ＡｃｔＲＩＩＢ的變體與其用途
AR065613A1 (es) * 2007-03-09 2009-06-17 Chugai Pharmaceutical Co Ltd Agentes de proteccion para organos transplantados
US20110123481A1 (en) * 2007-08-16 2011-05-26 Remedor Biomed Ltd. Erythropoietin and fibronectin compositions for therapeutic and cosmetic applications
WO2009143268A2 (en) * 2008-05-22 2009-11-26 Edison Pharmaceuticals, Inc. Treatment of mitochondrial diseases with an erythropoietin mimetic
US8216997B2 (en) 2008-08-14 2012-07-10 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
DK3750552T5 (da) 2008-08-14 2024-08-26 Acceleron Pharma Inc Gdf-fælder
MX355042B (es) 2009-06-08 2018-04-02 Acceleon Pharma Inc Metodos para aumentar adipositos termogenicos.
CN107267520A (zh) 2009-06-12 2017-10-20 阿塞勒隆制药公司 截短的actriib‑fc融合蛋白
KR102170682B1 (ko) * 2009-08-13 2020-10-28 악셀레론 파마 인코포레이티드 적혈구 수준을 증가시키기 위한 ｇｄｆ 트랩과 에리트로포이에틴 수용체 활성인자의 병용
ES2658292T3 (es) 2009-11-17 2018-03-09 Acceleron Pharma, Inc. Proteínas ActRIIB y variantes y usos de las mismas con respecto a la inducción de la utrofina para el tratamiento de la distrofia muscular
WO2012003960A1 (en) 2010-07-06 2012-01-12 Augustinus Bader Topical application of erythropoietin for the treatment of eye disorders and injuries
US9956265B2 (en) 2011-04-26 2018-05-01 Ajou University Industry-Academic Cooperation Foundation Composition for aiding surgical procedures for treating ischemic vascular diseases
RU2678117C2 (ru) 2012-11-02 2019-01-23 Селджин Корпорейшн Антагонисты активина-actrii и их применение для лечения нарушений костной ткани и других нарушений
US8992951B2 (en) 2013-01-09 2015-03-31 Sapna Life Sciences Corporation Formulations, procedures, methods and combinations thereof for reducing or preventing the development, or the risk of development, of neuropathology as a result of trauma
US20160279297A1 (en) * 2013-10-22 2016-09-29 ConcieValve LLC Methods for inhibiting stenosis, obstruction, or calcification of a stented heart valve or bioprosthesis
CN114699529A (zh) 2014-06-13 2022-07-05 阿塞勒隆制药公司 用于治疗溃疡的方法和组合物
US11241505B2 (en) * 2015-02-13 2022-02-08 Factor Bioscience Inc. Nucleic acid products and methods of administration thereof
CN105233256A (zh) * 2015-10-28 2016-01-13 中国人民解放军第三军医大学 促红细胞生成素及其衍生物在制备治疗疾病中促进凋亡细胞清除的药物中的应用
US11534466B2 (en) * 2016-03-09 2022-12-27 Aal Scientifics, Inc. Pancreatic stem cells and uses thereof
GB2550114A (en) * 2016-05-03 2017-11-15 Kymab Ltd Methods, regimens, combinations & antagonists
IL264439B2 (en) 2016-08-17 2024-08-01 Factor Bioscience Inc non-viral, cell-free composition comprising a synthetic messenger RNA (MRNA) encoding a gene-editing protein for use in treating cancer, and a synthetic RNA encoding a gene-editing protein for use in treatment
CN108114282B (zh) * 2016-11-28 2021-03-02 北京大学第三医院 他汀类化合物治疗缺血性疾病的用途
EP3620531A4 (en) 2017-05-02 2021-03-17 National Center of Neurology and Psychiatry METHOD OF PREDICTION AND EVALUATION OF THERAPEUTIC EFFECT IN DISEASES RELATING TO IL-6 AND NEUTROPHILS
WO2019078344A1 (ja) * 2017-10-20 2019-04-25 学校法人兵庫医科大学 抗ｉｌ－６受容体抗体を含有する術後の癒着を抑制するための医薬組成物
TWI822728B (zh) 2018-01-31 2023-11-21 加藤元一 含有il-6抑制劑的哮喘治療劑
RU2695334C1 (ru) * 2018-09-25 2019-07-23 Федеральное государственное автономное образовательное учреждение высшего образования "Белгородский государственный национальный исследовательский университет" (НИУ "БелГУ") Способ профилактики нарушений функций почек карбамилированным дарбэпоэтином в эксперименте
RU2678768C1 (ru) * 2018-09-25 2019-02-01 Федеральное государственное автономное образовательное учреждение высшего образования "Белгородский государственный национальный исследовательский университет" (НИУ "БелГУ") Способ профилактики ишемически-реперфузионных повреждений почек карбамилированным дарбэпоэтином в эксперименте
GB201815629D0 (en) 2018-09-25 2018-11-07 Kymab Ltd Antagonists
AU2020259884A1 (en) 2019-04-17 2021-10-07 Chugai Seiyaku Kabushiki Kaisha Therapeutic agent for urological cancer which is characterized by being administered with il-6 inhibitor and ccr2 inhibitor in combination
CA3145425A1 (en) 2019-07-03 2021-01-07 Factor Bioscience Inc. Cationic lipids and uses thereof
US10501404B1 (en) 2019-07-30 2019-12-10 Factor Bioscience Inc. Cationic lipids and transfection methods
EP4674480A3 (en) 2020-10-02 2026-04-08 Keros Therapeutics, Inc. Methods of using activin receptor type ii variants
CN119080909A (zh) * 2024-08-29 2024-12-06 深圳赛保尔生物药业有限公司 负载peg-epo及间充质干细胞的组合物、药物及其制备方法

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ210501A (en) 1983-12-13 1991-08-27 Kirin Amgen Inc Erythropoietin produced by procaryotic or eucaryotic expression of an exogenous dna sequence
IL77081A (en) 1984-12-04 1999-10-28 Genetics Inst Dna sequence encoding human erythropoietin process for the preparation thereof and a pharmaceutical composition of human erythropoietin
US4732889A (en) 1985-02-06 1988-03-22 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical composition for the treatment of the anemia of rheumatoid arthritis
EP0246322B1 (en) 1985-11-27 1992-08-26 Genetics Institute, Inc. Treatment of aids-type disease
US5198417A (en) * 1985-11-27 1993-03-30 Genetics Institute, Inc. Methods of treating pancytopenia and AIDS by co-administering EPO and colony stimulating factors
DK173067B1 (da) 1986-06-27 1999-12-13 Univ Washington Humant erythropoietin-gen, fremgangsmåde til ekspression deraf i transficerede cellelinier, de transficerede cellelinier sa
US5013718A (en) 1986-11-21 1991-05-07 Amgen, Inc. Method for treating iron overload using EPO
DE3729863A1 (de) * 1987-09-05 1989-03-16 Boehringer Mannheim Gmbh Stabilisierte erythropoietin-lyophilisate
AU4072189A (en) * 1988-02-24 1989-09-22 American National Red Cross, The Device for site directed neovascularization and method for same
US5024841A (en) * 1988-06-30 1991-06-18 Collagen Corporation Collagen wound healing matrices and process for their production
DE4014654A1 (de) 1990-05-08 1991-11-14 Behringwerke Ag Galenische waessrige formulierungen von erythropoietin und ihre verwendung
DK0575555T3 (da) * 1991-03-11 2001-11-05 Curis Inc Proteininduceret morfogenese
US5354934A (en) * 1993-02-04 1994-10-11 Amgen Inc. Pulmonary administration of erythropoietin
KR960701650A (ko) 1993-04-29 1996-03-28 찰스 엠. 브룩 에리트로포이에틴 유사체 조성물 및 방법(Eythropoietin analog compositions and methods)
IL110669A (en) 1993-08-17 2008-11-26 Kirin Amgen Inc Erythropoietin analogs
JPH08205860A (ja) * 1994-01-21 1996-08-13 Usa Government 造血細胞の膨大化および移植方法
ITFI940106A1 (it) * 1994-05-27 1995-11-27 Menarini Ricerche Sud Spa Molecola ibrida di formula gm-csf-l-epo o epo-l-gm-csf per la stimolaz ione eritropoietica
EP0784480B1 (en) 1994-11-03 2003-10-15 Boehringer Mannheim Gmbh Use of erythropoietin in the treatment of rheumatoid arthritis
US5837675A (en) * 1995-02-03 1998-11-17 Brox; Alan G. Synergistic effect of insulin-like growth factor-I and erythropoietin
US20020052309A1 (en) * 1996-09-11 2002-05-02 Athanasius A. Anagnostou Method of treating endothelial injury
US5980887A (en) * 1996-11-08 1999-11-09 St. Elizabeth's Medical Center Of Boston Methods for enhancing angiogenesis with endothelial progenitor cells
US6274158B1 (en) * 1998-02-04 2001-08-14 Veronica L. Zaharia Czeizler Treatment with recombinant human erythropoietin of bleeding in patients with normal and abnormal hemostasis
US6284260B1 (en) 1998-02-04 2001-09-04 Veronica L. Zaharia Czeizler Treatment with erythropoietin of bleeding from benign and malignant lesions with normal and abnormal coagulation parameters
DE19857609A1 (de) 1998-12-14 2000-06-15 Hannelore Ehrenreich Verwendung von Erythropoietin zur Behandlung von cerebralen Ischämien des Menschen
TR200103785T2 (tr) * 1999-04-13 2002-06-21 The Kenneth S. Warren Institute, Inc. Uyarılabilir doku işlevinin periferik olarak uygulanan eritropoietin vasıtasıyla düzenlenmesi
DE60131393D1 (de) 2000-05-02 2007-12-27 Action Pharma As Verfahren zur behandlung von erkrankungen assoziiert mit akuten entzündung unter nichtischämischen zustände
US7259146B2 (en) * 2000-05-26 2007-08-21 Ortho-Mcneil Pharmaceutical, Inc. Neuroprotective peptides
US7078376B1 (en) * 2000-08-11 2006-07-18 Baxter Healthcare S.A. Therapeutic methods for treating subjects with a recombinant erythropoietin having high activity and reduced side effects
US20020065214A1 (en) 2000-11-29 2002-05-30 Adrian Iaina Method of treating congestive heart failure
PA8536201A1 (es) 2000-12-29 2002-08-29 Kenneth S Warren Inst Inc Protección y mejoramiento de células, tejidos y órganos que responden a la eritropoyetina
JP2005503127A (ja) * 2001-04-04 2005-02-03 ジェンオディセ エリスロポエチン遺伝子の新規ポリヌクレオチド及びポリペプチド
US6784154B2 (en) * 2001-11-01 2004-08-31 University Of Utah Research Foundation Method of use of erythropoietin to treat ischemic acute renal failure
CA2468499A1 (en) * 2001-11-28 2003-06-05 Ortho-Mcneil Pharmaceutical, Inc. Erythropoietin dosing regimen for treating anemia
US7335490B2 (en) 2002-01-09 2008-02-26 Crucell Holland B.V. Use of erythropoietin for the preventive or curative treatment of cardiac failure
US6748154B2 (en) * 2002-03-28 2004-06-08 Nortel Networks Limited Optical module access tray
DE10234192B4 (de) * 2002-07-26 2009-11-26 Epoplus Gmbh Co.Kg Verwendung von Erythropoetin
DE102004004509B4 (de) * 2004-01-23 2010-07-01 Epoplus Gmbh Co.Kg Einsatz von niedrig dosiertem Erythropoietin zur Stimulation endothelialer Vorläuferzellen sowie zur Organregeneration und Progressionsverlangsamung von Endorganschäden

Similar Documents

Publication Publication Date Title
IL223783B (en) Compound 1-converted indole for use in the treatment of a disease or condition, a pharmaceutical preparation containing the compound and use of the compound to prepare a medicine
CL2014002556A1 (es) Compuestos derivados de ácidos indaniloxidihidrobenzofuranilacéticos, agonistas del receptor gpr40; composiicon farmaceutica; y su uso en el tratamiento de enfermedades o afecciones como diabetes, resistencia a la insulina, obesidad, entre otras.
CL2013002474A1 (es) Compuestos derivados de piperidina puenteada (3-aza-biciclo[3.2.1]oct-8-il), moduladores de b-amiloide; procedimiento de preparación; composición farmacéutica; y uso en el tratamiento de enfermedades tales como alzheimer, síndrome de down, entre otras.
BR112014014262A2 (pt) nanopartículas; composição farmacêutica; método de administrar um ou mais agentes terapêuticos, profiláticos, e/ou diagnósticos a um paciente em necessidade dos mesmos e método de preparação das partículas.
HK1218836A1 (zh) 协同细菌组合物和其制造方法和用途
IL232308A (en) Compounds as modulators of atp-linked casting, pharmaceuticals containing them and their use in the preparation of drugs for the treatment of diseases and processes for their preparation
EA201391521A1 (ru) Композиции и способы для ингибирования и/или модулирования эффекторных t-клеток, участвующих в воспалительном нейродегенеративном заболевании
EP2718317A4 (en) GLUCOSE-DEPENDENT INSULINOTROPE POLYPEPTIDE ANALOGUE, PHARMACEUTICAL COMPOSITIONS AND THEIR USE
MX366090B (es) Combinación farmacéutica para usarse en mejorar la tolerancia a la glucosa en pacientes que padecen diabetes de tipo 2.
SI2750699T1 (sl) Farmacevtska kombinacija, za uporabo pri glikemični kontroli pri pacientih, ki imajo sladkorno bolezen tipa 2
BR112013029256A8 (pt) combinação farmacêutica para uso no tratamento de pacientes com diabetes tipo 2
PL2611458T3 (pl) Zastosowanie AVE0010 do produkcji leku do leczenia cukrzycy typu 2
PH12015500746A1 (en) Benzamides
IL226386A0 (en) Medical treatment for metabolic syndrome, type 2 diabetes, obesity or pre-diabetes
LT2013018A (lt) Farmacinė kompozicija, skirta gydyti diabetą ir metabolinius sutrikimus
JP2016500312A5 (enExample)
FR2996838B1 (fr) Procede de preparation d'un oxyde mixte de titane et de niobium par traitement solvothermal ; electrode et accumulateur au lithium comprenant ledit oxyde mixte
PH12012502082A1 (en) Combination of active loaded granules with additional actives
PE20141012A1 (es) Dimaleato de 9-[4-(3-cloro-2-fluoro-fenilamino)-7-metoxi-quinazolin-6-iloxi]-1,4-diaza-espiro[5.5]undecan-5-ona, su uso como medicamento y su preparacion
JP2012518646A5 (enExample)
WO2012092305A3 (en) Nanonized iron compositions and methods of use thereof
ZA201007391B (en) Use of dronedarone or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for regulating the potassium in the blood
EP2606898A4 (en) COMPOSITION WITH LIGUSTROFLAVONE, RHOIFOLIN AND HYPERIN AND THEIR USE IN THE MANUFACTURE OF A MEDICAMENT
MX360047B (es) Unidad sólida con alto contenido en fexofenadina y su procedimiento de preparación.
JP2013100370A5 (enExample)